The Medicines Company  

(Public, NASDAQ:MDCO)   Watch this stock  
Find more results for BRISTOL-MYERS SQUIBB COMPANY�
26.05
+1.04 (4.16%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.65 - 26.08
52 week 23.53 - 41.28
Open 25.30
Vol / Avg. 861,218.00/1.25M
Mkt cap 1.68B
P/E 114.83
Div/yield     -
EPS 0.23
Shares 64.68M
Beta 0.65
Inst. own 103%
Jul 21, 2014
Q2 2014 The Medicines Company Earnings Release (Estimated) Add to calendar
Apr 23, 2014
Q1 2014 The Medicines Company Earnings Release
Apr 23, 2014
Q1 2014 The Medicines Company Earnings Conference Call - Webcast
Mar 12, 2014
The Medicines Company at Barclays Healthcare Conference - Webcast
Mar 7, 2014
The Medicines Company Acute Cardiovascular Care Investor and Analyst Meeting
Feb 25, 2014
The Medicines Company at RBC Capital Markets Healthcare Conference
Feb 24, 2014
The Medicines Company at Citi Global Healthcare Conference
Feb 19, 2014
Q4 2013 The Medicines Company Earnings Release
Feb 19, 2014
Q4 2013 The Medicines Company Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 0.59% 2.22%
Operating margin -8.57% 1.92%
EBITD margin - 6.60%
Return on average assets 0.27% 1.12%
Return on average equity 0.55% 2.10%
Employees 571 -
CDP Score - -

Address

8 SYLVAN WAY
PARSIPPANY, NJ 07054
United States - Map
+1-973-2906000 (Phone)
+1-973-6569898 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products. In January 2013, the Company acquired Incline Therapeutics Inc. Effective August 5, 2013, The Medicines Company acquired the entire interest of ProFibrix BV, a biotechnology company. Effective December 4, 2013, The Medicines Co acquired Rempex Pharmaceuticals Inc.

Officers and directors

Clive A. Meanwell M.D., Ph.D. Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Glenn P. Sblendorio President, Chief Financial Officer, Director
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
William B. O'Connor Senior Vice President, Chief Accounting Officer
Age: 54
Bio & Compensation  - Reuters
Stephen M. Rodin Senior Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Elizabeth H.S. Wyatt Lead Independent Director
Age: 65
Bio & Compensation  - Reuters
William W. Crouse Independent Director
Bio & Compensation  - Reuters
Robert J. Hugin Independent Director
Age: 58
Bio & Compensation  - Reuters
John C. Kelly Independent Director
Age: 70
Bio & Compensation  - Reuters
Armin M. Kessler Independent Director
Age: 75
Bio & Compensation  - Reuters